Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.35 |
| ▸ | APOL1 | O14791 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15587436 | 0.81 | RPS6KB1 (0.37) | CACNA1BAPOL1CYP2D6KCNH2KMT2A | |
| SCHEMBL19008151 | 0.79 | BCHE (0.50) | CTSDBACE1CACNA1BCYP2D6KCNH2 | |
| SCHEMBL17563740 | 0.78 | CTSD (0.36) | CTSDBACE1 | |
| SCHEMBL18672910 | 0.78 | RAB9A (0.47) | MEN1KMT2A | |
| SCHEMBL18626594 | 0.77 | MAP4K4 (0.43) | CTSDBACE1MEN1KMT2A | |
| SCHEMBL19008154 | 0.75 | MAP4K4 (0.44) | CTSDBACE1 | |
| SCHEMBL18626561 | 0.75 | GSR (0.44) | CTSDBACE1MEN1KMT2A | |
| SCHEMBL18626534 | 0.72 | MAP4K4 (0.42) | CTSDBACE1CYP2D6KCNH2MEN1 | |
| SCHEMBL18626562 | 0.71 | MAP4K4 (0.41) | CTSDBACE1KCNH2MEN1KMT2A | |
| SCHEMBL17896303 | 0.70 | MAP4K4 (0.53) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | CTSD 3865/4885BACE1 3929/4885CACNA1B 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.